Bharat Biotech Company Pras

www.bharatbiotech.com

Corporate Profile 2014


Fast Facts

Issues

Products

R&D Pipeline

Projects

Recognition

Executive Summary


Fast Facts


Fast Facts Issues Products R&D Pipeline Projects Recognition

Established : 1996

Promoters : Dr. Krishna & Ms. Suchitra Ella

Business Line : Vaccines and Bio-therapeutics

First Project : Hepatitis B Vaccine - US $ 3.5 Mn

Investment : Over US $ 150 Mn till date

Facility : One of the largest facilities in Asia

Personnel : 700 resources including scientists

Accreditations : Korean FDA, ANVISA, other Countries

Innovation : 50 Global patents

Vision

Mission

To offer affordable, safe and effective healthcare

solutions to combat mankind's most dreaded illnesses, and to

thus eradicate or at least control their occurrence in the years to

come.

Developing next-generation remedies through Genetic

Engineering Technologies so as to create a healthier world.

Mission 7 Billion


Issues


Products R&D Pipeline Projects Recognition

Emerging Country Challenges

Lack of clarity on disease burden, public health focus & policies

NEG

LEC

TED

AP

PR

OA

CH

NEG

LEC

TED

DIS

EASE

S

1 TYPHOID

2 HEPATITIS

3 ROTA

4 SCHISTOSOMIASIS

5 E. COLI

6 CHOLERA

7 OTHER DIARRHEA

1 JE

2 DENGUE

3 CHIKUNGUNYA

4 MALARIA

5 TRYPANOSOMA

6 LEISHMANIA

7 FILARIA

POLITICAL COMMITTMENT

SCIENTIFIC COMMITTMENT

Fast Facts Issues



Thinking Future

Todays neglected diseases - Tomorrows global diseases

1 PLAGUE

2 HIV

3 INFLUENZA

4 MALARIA

1 DENGUE

2 CHIKUNGUNYA

3 TRYPANOSOMA

4 LEISHMANIA

5 FILARIA

6 JAPANESE ENCEPHALITIS

Fast Facts Issues

No DW manufactures develop new vaccines. Most DW manufactures are biogeneric players. DC manufactures follow MNCs. Our Mission is to change that mindset.

NEGLECTED DISEASES

GLOBAL DISEASES


Emerging Market Value Proposition

Bharat Biotech Strategy

Population

Birth Cohort

Health Care Budgets Increasing

Health Care Budgets Decreasing

Our growth path for future is here

Emerging

6 Billion

125 Million

Low Value

High Volume

Products R&D Pipeline Projects Recognition Fast Facts Issues

Developed

0.75 Billion

7.5 Million

High Value

Low Volume


Products


JE Launch

The Union Health & Family Welfare Minister, Shri Ghulam Nabi Azad launching

Japanese Encephalitis vaccine on 04th October, 2013 in New Delhi

Products R&D Pipeline Projects Recognition Issues Fast Facts

Purified, Inactivated Japanese Encephalitis Vaccine

1st indigenously developed


TCV Launch


Vi Capsular Polysaccharide Tetanus Toxoid Conjugate Vaccine

Worlds 1st Clinically Proven Typhoid Conjugate Vaccine

Dr. Christian Loucq - International Vaccine Institute Director-General launching

Typhoid Conjugate Vaccine in Hyderabad on 26th August, 2013



Product Launches

Dr. A.P.J. Abdul Kalam Former President of India, launching

Dr. John Robbins Father of Polysaccharide Vaccine National Institute of Health, USA, launching

Dr. Julie Gerberding Former Director of the U.S. Centers for Disease Control, launching

Issues Fast Facts


Vaccines

Wide Product Portfolio

S. No. Vaccine Brand

1 DPT+ Hep B + Hib Comvac 5

2 DPT+ Hep B Comvac 4-Hb

3 DPT; TT, DT Comvac 3

4 Hep B Revac B+

5 Hep B Revac B mcf

6 Hib BioHib

7 Typhoid Typbar

8 Typhoid Typbar TCV

9 OPV Trivalent BIOPOLIO

10 OPV Monovalent Type-1 BIOPOLIO M1

11 OPV Monovalent Type-3 BIOPOLIO M3

12 OPV Bivalent BIOPOLIO B1/3

13 JE Jenvac



1 Typhoid Typbar


3 Rabies INDIRAB

4 Influenza HN VAC

5 JE Jenvac


1 Typhoid Typbar


3 Influenza HN VAC

4 JE Jenvac

Children & Adult

Traveler

Children


Bio-therapeutics

Wide Product Portfolio


S. No. Bio-therapeutic Brand

1 Probiotic Yeast BIOGIT

2 Recombinant Human Epidermal Growth Factor

REGEN-D

3 Recombinant Human Epidermal Growth Factor, Silver Sulfadiazine & Chlorexidine Gluconate Cream

SLVRGEN

4 Zinc with ORS ZELECT


Product Distribution

More than 2 Billion doses delivered



More than 2 Billion doses delivered


Korea

Nepal

Philippines

Brazil

(ANVISA)

Sri Lanka

Saudi Arabia

Colombia

(INVIMA)

Ghana Kenya Congo

Turkey Kazakhstan

Uganda

Syria

Malawi

Ukraine

Belarus

Ivory Coast

Accreditation

Pakistan Myanmar


R&D Pipeline



Pipeline Products

1st Time in the world Typhoid Conjugate Vaccine

S. No. Vaccines Product Development Preclinical

Testing Phase I Phase II Phase III Commercial

License

1 Chikungunya 2017

2 Malaria PvRII 2017

3 Staph Aureus MRSA 2018

4 Human Papilloma Virus 2018

5 Acellular Pertussis 2016

6 Tetanus (Meat Free) 2016

7 S. Paratyphi 2018

8 NTS Conjugates 2018

9 Sabin IPV 2018

Therapeutics Product Development Preclinical

Testing Phase I Phase II Phase III Commercial

License

1 THR-100 2015

2 Lysostaphin Topical 2015

3 Lysostaphin IV 2017

4 r Human Serum Albumin 2014

Issues Fast Facts


Projects


Recognition


Recognition of Achievements

Young Enterprising Company


VOA awards 2013 most promising vaccines for paediatric

16th March, 2013

Pharma Bio World Award

Business Leader of the Year

Biotechnology 2011

Best R&D Company of the year 2010

by Pharmaceutical Leadership Summit

2010 Mumbai

National Technology

Award Govt of India 2006

Business Innovation Marico Foundation

& Business World 2006


Recognition of Achievements

Young Enterprising Company


JRD TATA Best Entrepreneur award FICCI Award Excellence in Science

Best Performance in Technology

Marico Foundation Innovation Award

TDB National award DBT-award for Product & Process


Our mission is to address the health care needs of emerging markets, drive innovation, be a front runner in research and development of

new vaccines and bio-therapeutics

Mission 7 Billion

Dr. Krishna M. Ella Chairman & Managing Director


Thank You

Address


Bharat Biotech International Limited Genome Valley, Shameerpet Mandal,

Ranga Reddy District - 500 078 Andhra Pradesh, India.

Tel.: +91 40 2348 0567 Fax: +91 40 2348 0560

[email protected] www.bharatbiotech.com

Bharat Biotech Company Pras

Documents

Transcript of Bharat Biotech Company Pras